Hughes. D.A.

study patient warfarin –effectivenes coumarin dosing cost –effectiveness genotyping event atrial fibrillation anticoagulation stroke anticoagulant atrial fibrillation effectiveness therapy treatment coumarin derivatives review range trial health country group result university science percentage time evaluation pharmacogenetic future quality difference genotype-guided derivative netherland strategy genotype-guided dosing cyp 2c analyses pharmacogenetic-guided dosing anticoagulant therapy thromboembolic events vkorc anticoagulant care acenocoumarol european countries target inr range monitoring clinic measurement thromboembolic percentage phenprocoumon pharmacogenomic 100  patient-years month healthcare ratio management austria ana ­ysis complication incidence verhoef european cost –effectiveness analyses genotype-guided dosing strategy sweden target hospital redekop germany mcwilliam outcome consequence sensitivity dabigatran 100